AKT1 and neoplasm: Treating genetically diverse glioblastoma cell lines with PP242 but not with rapamycin results in a dramatic and long-lasting reduction in AKT phosphorylation on serine 473, inhibiting tumor growth and invasiveness and preventing GSC proliferation [17].